{
    "nctId": "NCT00647218",
    "briefTitle": "Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer",
    "officialTitle": "A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 38,
    "primaryOutcomeMeasure": "Pathologic Complete Response Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically documented invasive carcinoma of the breast\\*\n\n  * Tumor \u2265 2 cm in greatest dimension (e.g., T2-4) and any nodal status (e.g., N0-3), including locally advanced disease, as defined by the following criteria:\n\n    * Primary tumor \u2265 5 cm\n    * Tumor of any size with direct extension to the chest wall or skin\n    * Inflammatory breast cancer (T4d)\n    * Metastasis to ipsilateral internal mammary node\n    * Ipsilateral lymph nodes that are clinically fixed to each other or to other structures (N2) NOTE: \\*Diagnosis may be made by core or tru-cut biopsies\n* Measurable or evaluable tumor\n\n  * Measurable disease is defined as any mass that can be reproducibly measured in two perpendicular dimensions\n  * Evaluable disease is defined as any lesion visible by mammogram or palpable by physical exam that does not fit the above criteria of measurability\n* Planning to undergo breast conservation surgery\n* Willing to undergo AND is a candidate for radiotherapy, in the judgement of the treating radiation oncologist\n* No evidence of distant metastatic disease (e.g., lung, liver, bone, brain)\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-1\n* WBC \u2265 3,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN\n* Left ventricular ejection fraction \u2265 45%\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other malignancies within the past 5 years, except curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix\n* No history of hypersensitivity reaction to products containing polysorbate 80 (Tween 80)\n* No serious medical illness that, in the judgment of the treating physician, places the patient at risk\n* No peripheral neuropathy \u2265 grade 2\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior tamoxifen as chemoprevention allowed\n* No prior radiotherapy to the ipsilateral breast\n\n  * Prior radiotherapy to the contralateral breast is allowed\n* No prior chemotherapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}